BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12152158)

  • 1. Human DNA topoisomerase I: An anticancer drug target present in human sarcomas.
    Coleman LW; Rohr LR; Bronstein IB; Holden JA
    Hum Pathol; 2002 Jun; 33(6):599-607. PubMed ID: 12152158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas.
    Coleman LW; Bronstein IB; Holden JA
    Anticancer Res; 2001; 21(2A):1167-72. PubMed ID: 11396158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression.
    Monnin KA; Bronstein IB; Gaffney DK; Holden JA
    Hum Pathol; 1999 Apr; 30(4):384-91. PubMed ID: 10208458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas.
    Hafian H; Venteo L; Sukhanova A; Nabiev I; Lefevre B; Pluot M
    Hum Pathol; 2004 Jun; 35(6):745-51. PubMed ID: 15188142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma.
    Lynch BJ; Komaromy-Hiller G; Bronstein IB; Holden JA
    Hum Pathol; 1998 Nov; 29(11):1240-5. PubMed ID: 9824101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
    Staley BE; Samowitz WS; Bronstein IB; Holden JA
    Mod Pathol; 1999 Apr; 12(4):356-61. PubMed ID: 10229499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival.
    Gupta D; Bronstein IB; Holden JA
    Hum Pathol; 2000 Feb; 31(2):214-9. PubMed ID: 10685636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
    Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
    Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas.
    Coleman LW; Perkins SL; Bronstein IB; Holden JA
    Hum Pathol; 2000 Jun; 31(6):728-33. PubMed ID: 10872667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer.
    Lynch BJ; Guinee DG; Holden JA
    Hum Pathol; 1997 Oct; 28(10):1180-8. PubMed ID: 9343325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas.
    Lee SJ; Kim HS; Kim HS; Chun YK; Hong SR; Lee JH
    Hum Pathol; 2007 Aug; 38(8):1226-31. PubMed ID: 17490723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear factor-Y binding to the topoisomerase IIalpha promoter is inhibited by both the p53 tumor suppressor and anticancer drugs.
    Joshi AA; Wu Z; Reed RF; Suttle DP
    Mol Pharmacol; 2003 Feb; 63(2):359-67. PubMed ID: 12527807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 dependence of topoisomerase I recruitment in vivo.
    Mao Y; Okada S; Chang LS; Muller MT
    Cancer Res; 2000 Aug; 60(16):4538-43. PubMed ID: 10969804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival.
    Holden JA; Townsend JJ
    Mod Pathol; 1999 Dec; 12(12):1094-100. PubMed ID: 10619260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies.
    Bronstein IB; Vorobyev S; Timofeev A; Jolles CJ; Alder SL; Holden JA
    Oncol Res; 1996; 8(1):17-25. PubMed ID: 8704283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
    Holden JA
    Ann Clin Lab Sci; 1997; 27(6):402-12. PubMed ID: 9433537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical staining for DNA topoisomerase IIa in Hodgkin's disease.
    Brown MS; Holden JA; Rahn MP; Perkins SL
    Am J Clin Pathol; 1998 Jan; 109(1):39-44. PubMed ID: 9426516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor.
    Tanoguchi K; Sasano H; Yabuki N; Kikuchi A; Ito K; Sato S; Yajima A
    Mod Pathol; 1998 Feb; 11(2):186-93. PubMed ID: 9504690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-Elemene Inhibits Cell Proliferation by Regulating the Expression and Activity of Topoisomerases I and IIα in Human Hepatocarcinoma HepG-2 Cells.
    Gong M; Liu Y; Zhang J; Gao YJ; Zhai PP; Su X; Li X; Li Y; Hou L; Cui XN
    Biomed Res Int; 2015; 2015():153987. PubMed ID: 26221582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential immunohistochemical staining for DNA topoisomerase II alpha and beta in human tissues and for DNA topoisomerase II beta in non-Hodgkin's lymphomas.
    Bauman ME; Holden JA; Brown KA; Harker WG; Perkins SL
    Mod Pathol; 1997 Mar; 10(3):168-75. PubMed ID: 9071722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.